STOCK TITAN

Cingulate (CING) EVP granted 5,475 shares; 2,086 withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cingulate Inc. executive Nilay Dahyabhai Patel, EVP, CLO and CCO, received a grant of 5,475 shares of common stock on March 9, 2026. The shares were awarded under Cingulate’s 2021 Omnibus Equity Incentive Plan as part of Patel’s 2025 bonus. To cover related tax obligations, 2,086 shares otherwise issuable were withheld, leaving Patel with 3,389 shares of common stock held directly after these transactions.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patel Nilay Dahyabhai

(Last) (First) (Middle)
1901 W. 47TH PLACE

(Street)
KANSAS CITY KS 66205

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cingulate Inc. [ CING ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, CLO and CCO
3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 03/09/2026 A 5,475 A $0 5,475 D
Common Stock(2) 03/09/2026 F 2,086 D $0 3,389 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares of common stock were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended, for a portion of the Reporting Person's 2025 bonus.
2. Shares otherwise issuable were withheld to satisfy the Reporting Person's tax obligations on the grant described in footnote 1 above.
/s/ Nilay D. Patel 03/11/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cingulate (CING) report for Nilay Dahyabhai Patel?

Cingulate reported that EVP, CLO and CCO Nilay Dahyabhai Patel received 5,475 common shares as a stock grant. The award was made under the 2021 Omnibus Equity Incentive Plan as part of his 2025 bonus compensation.

How many Cingulate (CING) shares were withheld for taxes in Patel’s Form 4?

The Form 4 shows 2,086 Cingulate common shares were withheld to satisfy Patel’s tax obligations. These shares were otherwise issuable from the same 5,475-share grant tied to his 2025 bonus compensation.

What is Nilay Dahyabhai Patel’s share ownership after the reported Cingulate (CING) transactions?

After the grant and related tax withholding, Patel directly holds 3,389 Cingulate common shares. This figure reflects the 5,475-share bonus award net of 2,086 shares withheld for tax obligations on the grant.

Under which plan was Nilay Dahyabhai Patel’s Cingulate (CING) stock grant issued?

The common stock granted to Patel was issued under Cingulate’s 2021 Omnibus Equity Incentive Plan, as amended. The footnotes specify the grant represents a portion of his 2025 bonus compensation paid in equity.

Does the Cingulate (CING) Form 4 show open-market buying or selling by Patel?

The Form 4 does not show open-market buying or selling. It reports a stock grant of 5,475 shares as compensation and a related tax-withholding disposition of 2,086 shares, both categorized as non-derivative transactions.
Cingulate Inc

NASDAQ:CING

View CING Stock Overview

CING Rankings

CING Latest News

CING Latest SEC Filings

CING Stock Data

95.06M
8.75M
Biotechnology
Pharmaceutical Preparations
Link
United States
KANSAS CITY